Organisation paid for research Program year 2023 Source: CMS Open Payments

Clinical Trial Receipts

Neither a doctor nor a teaching hospital

Research payments

$198,807

31 payments

Through program year 2023, Clinical Trial Receipts is reported as receiving $198,807 in research payments, across 31 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $18,590 4
2022 Research $11,620 2
2021 Research $62,070 10
2020 Research $87,357 13
2019 Research $19,170 2

Breakdown

Who paid Research payments · program years 2019–2023
  1. Takeda Pharmaceuticals U.S.A., Inc. $137,344 19 payments
  2. AstraZeneca Pharmaceuticals LP $61,462 12 payments
Studies the money was for Research payments · program years 2019–2023
  1. An Open Label Extension of Study Hgt-Hit-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With Elaprase in Patients With Hunter Syndrome and Cognitive Impairment $87,357 13 payments
  2. An Open Label Extension of Study Hgt-Hit-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With Elaprase in Patients With Hunter Syndrome and Cognitive Impairment $49,988 6 payments
  3. A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) $27,640 5 payments
  4. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) $19,170 2 payments
  5. A 54 Week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Parallel Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $5,500 1 payment
  6. A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy $4,000 1 payment
  7. Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneously SC in adult participants with symptomatic COPD and history of 2 moderate or 1 severe exacerbation of COPD in the previous 12 months $2,924 2 payments
  8. A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis FRONTIER 4 $2,228 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record